Expert Compounding Pharmacy, Lake Balboa, CA

Is Expert Compounding Pharmacy registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Expert Compounding Pharmacy hold a California pharmacy license?

The California State Board of Pharmacy lists license PHY 50124 for Expert Compounding Pharmacy Inc, Lake Balboa, status Active, as of Nov 6, 2026.

Has Expert Compounding Pharmacy had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 untitled letter (Aug 26, 2022) and 1 FMD-145 letter (Jan 6, 2023) for Expert Compounding Pharmacy. State board actions: no California State Board of Pharmacy action on license PHY 50124 or under this exact name and city was found in the board’s posted disciplinary decisions on facility licenses (actions dated Jan 5, 2005 to Oct 28, 2026) on Nov 6, 2026.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Expert Compounding Pharmacy
Location
Lake Balboa, CA
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Jan 6, 2023
FDA Data Dashboard inspections
1 inspection: 1 VAI; 2 published Form 483s
Form 483 text on this page
2 Form 483s, 12 observations
State board records
License found: PHY 50124, Active

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Expert Compounding Pharmacy, a 503A facility, with 3 dated actions.

Document
Jan 6, 2023FMD-145 letterFMD-145 Letter Issued 01/06/2023Not linked by FDA
Aug 26, 2022Untitled letterUntitled Letter Issued 08/26/2022FDA copy (archived)
Mar 4, 2022Form 483483 Issued 03/04/2022FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Expert Compounding Pharmacy, Lake Balboa, CA (FEI number 3010681729), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Mar 4, 2022Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30106817291164537

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 12 numbered observations in all, across 2 inspections ending Mar 4, 2022 to Mar 4, 2022. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection dated Mar 4, 2022 by FDA (dates on the form not read): 6 observations

Firm on the cover
Expert Compounding Pharmacy, 6744 Balboa Boulevard, Lake Balboa, CA 91406
FEI number
3010681729
Establishment type on the cover
Producer of Non-Sterile Drugs
FDA district office on the cover
19701 Fairchild Irvine, CA 92612 -2445
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

You produced hazardous drugs without providing adequate cleaning of utensils to prevent cross-contamination.

SpecificaJly,

Your firm has not taken adequate steps to ensure the procedures for cleaning non-product dedicated utensils used in drug manufacturing operations effectively remove all contaminants. The procedure used by your firm to clean non-product dedicated utensils used for hormone drug production does not include a deactivating agent to prevent cross-contamination of residues from prior production operations between hormone drug lots. Your firm has released and distributed munerous lots of drug products without ensuring they have not been cross contaminated with residues from other hormone products, including but not limited to the following:

• Testosterone <Redacted B4>% gel, <Redacted B4>gm, lot 02222022:76, exp 08/14/22, exp 08/21/22, compounded 02/22/22 to fill Rx <Redacted B4>

¾ • Estradiol/Estriol/Progesterone/Testosterone <Redacte d B4>mg/gm cream, <Redacted B4>gm, lot 022120 22:09, exp 08/20/22, compounded 02/21/22 t o fill Rx <Redacted B6>

Observation 2

Non-microbial contamination was observed in your production area.

SpecificaJly,

a) The ceiling of your <Redacted B4> Room, vvhich is used to manufacture drug products containing hormones, contains two air inlet vents, one of which was visibly covered with apparent dust build-up on 02/24/22. That same day, I observed the manufacture of the following drug product lots in the <Redacted B4> (of <Redacted B4> Room while air could be felt actively being blown into the room through the vents:

hormones, contains two air inlet vents, one of which was visibly covered with apparent dust build-up on 02/24/22. That same day, I obsenred the manufacture of the following drug product lots in the r ·(of(4) J Room while air could be felt actively being blown into the room through the vents:

• Liothyronine (D )/Methocel (Veg) <Redacted B4> mcg capsules, <Redacted B4> units, lot 02232022:96

• Prooesterone <Redacted B4>mg per <Redacted B4>mL drops, <Redacted B4>mL, lot 0223202224

• Estradiol <Redacted B4> mg/Estriol <Redacted B4> mg/Progesterone <Redacted B4> mg/Testosterone <Redacted B4> mg per gm cream, <Redacted B4> lot 02242022:63 ...

Read the full 483 (PDF on fda.gov)

Observation 3

You used a non-pharmaceutical grade component in the formulation of a drug product.

Specifically,

a) Your firm uses non-pharmaceutical grade <Redacted B4> in the production of non-sterile drug products.

b) Your firm does not perform anaJytical or microbiological testing of this component to determine whether the <Redacted B4> rneets the specifications for <Redacted B4> , USP.

Observation 4

Testing and release of drug product for distribution do not include appropriate laboratory detennination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.

SpecificaJly,

Your firm does not perform quality control testing on finished drug products to ensure their identity, strength, purity, and quality prior to lot release. Your firm has released and distributed numerous lots of drug products without testing to ensure safety and efficacy, including but not limited to the following:

• Lidocaine/Tetracaine <Redacted B4>% LT microsomal base cream, <Redacted B4>kg, lot 05062021 :64, exp 11/02/21, compounded 05/06/21 to fill Rx <Redacted B6> (non-patient specific)

• Benzocaine/Lidocaine/Tetracaine <Redacted B4>% microsomal base cream, <Redacted B4>kg, lot 05072021:72, exp 11/03/21, compounded0 5/07/21 to fill Rx <Redacted B6> (non-patient specific)

• Doxycycline (vet) <Redacted B4> mg/mL suspension, <Redacted B4> mL, lot 11292021:39, exp 05/28/22, compounded 11/29/21 to fill Rx <Redacted B6> (non-patient specific)

Observation 5

Laboratory controls do not include determination of conformance to appropriate written specifications for the acceptance of each lot within each shipment of components used in the manufacture, processing, packing, or holding of drug products.

Specifically,

Your firm does not perform any analytical testing of incoming raw materials used in the manufacturing of drug products to ensure they conform to requirements for identity, strength, purity, and quality. Your firm has released and distributed numerous lots of drug products without ensuring the components in them are fir for use, including but not limited to the following:

• Lidocaine/Tetracaine <Redacted B4>% LT microsomal base cream, <Redacted B4>kg, lot 05062021 :64, exp 11/02/21, compounded 05/06/21 to fill Rx <Redacted B4> (non-patient specific)

• Doxycycline (vet) <Redacted B4> mg/mL suspensio, <Redacted B4> mL, lot 11292021:39, exp 05/28/22, compounded 11/29/21 to fill Rx (<Redacted B6> (non-patient specific)

Observation 6

The batch production and control records are deficient in that they do not include documentation of the accomplishment of each significant step in manufacturing and processing.

Specifically,

a) Your firm does not document actual weights and measurements of components used in the manufacture of drug products on the Logged Formula Worksheets which serve as batch records for drug product lots.

b) Your firm does not document the specific pieces of equipment used in the manufacture of drug products, including analytical balances and <Redacted B4> mixing machines.

Due to these practices, your firm has released and distributed numerous lots of drug products for which you do not have records documenting the actual amounts of the components or specific pieces of equipment that were used to manufacture them, including but not limited to the following:

• Lidocaine/Tetracaine <Redacted B4>% LT microsomal base cream, <Redacted B4> kg, lot 05062021:64, exp 11/02/21, compounded 05/06/21 to fill Rx (<Redacted B6> (non-patient specific) ...

Read the full 483 (PDF on fda.gov)

Inspection Feb 23, 2022 to Mar 4, 2022: 6 observations

Firm on the cover
Expert Compounding Pharmacy, 6744 Balboa Boulevard, Producer of Non-Sterile Drugs This documentlists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. lf you have an objection regarding an observation, or have implemented, or plan to implement, correclive action in response to an observation,you may discuss the objection or action with the FDA represenmtive(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.
FEI number
3010681729
FDA district office on the cover
Irvine, CA. 92612--2445
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

You produced hazardous drugs without providing adequate cleaning of utensils to prevent cross-contamination.

Specifically,

You r firm has not taken adequate steps to ensure the procedures for cleaning non-product dedicated utensils used in drug manufacturing operations effectively remove all contaminants. The procedure used by your firm to clean non-product dedicated utensils used for hormone drug production does not include a deactivating agent to prevent cross-contamination of residues from prior productions operations between hormone drug lots. Your firm has released and distributed numerous lots of drug products without ensuring they have not been cross contaminated with residues from other hormone products, including but not limited to the following:

• Testosteron e <Redact ed B4> % ge l, <Redacted B> gm, lot 02222022:76,exp 08/14/22, exp 08/2

1/22, compou nded 0 2/22/22 to fill Rx <Redacted B4> • Estradiol/Estriol/Progesterone/Testosterone <Redacted B4> mg/gm cream, <Redacted B4>, gm, lot 02212022:09, exp 08/20/22, compounded 02/21/22 to fill Rx <Redacted B4>

Observation 2

Non-microbial contamination was observed in your production area.

Specifically,

a) The ceiling of your <Redacted B4> Room, which is used to manufacture drug productss containing hormones, contains two air inlet vents, one of which was visibly covered covered with apparent dust build-up on 02/24/22. That same day, I observed the manufacture of the following drug product lots in the <Redacted B4> Room while air could be felt actively being blown into the room through the events.

• Progesterone <Redacted B4> mg suppositories, <Redacted B4> units, lot 02242022:42

b) The ceiling of the general compounding area in your facility consists of tiles made of an uncleanable porous <Redacted B4> material suspended <Redacted B4> grid framework. On 02/23/22 I observed build-up of dirt and foreign materials on both the <Redacted B4> tiles an <Redacted B4> grid in areas above and around the compounding stations used in non-homorne drug manufacturing operations. That same day, I witnessed the compounding of the following drug product lots in two of these areas, with components of each exposed. to the ceiling above during weighing and transfer steps: ...

Read the full 483 (PDF on fda.gov)

Observation 3

You used a non-pharmaceutical grade component in the formulation of a drug product.

Specifically,

a) Your firm uses non-pharmaceutical grade <Redacted B4> in the production of non-sterile drug products.

b) Your firm does not perform analytical or microbiological testing of this component to determine whether the <Redacted B4> meets the specifications for <Redacted B4> , USP.

Observation 4

Your firm does not perform qualiy control testing on finished drug product, to ensure their identity, strength, purity, and quality prior to lot release. Your firm has released and distributed numerous lots of drug products without testing to ensure safety and efficacy, including but not limited to the following:

• Lidocaine/Tetracaine <Redacted B4>%LT microsomal base cream, <Redacted B4>kg, lot 0 5062021 :64, exp 11/02/21, compounded 05/06/21 to fill Rx <Redacted B4> (non-patient specific)

• Benzocaine/Lidocaine/Tetracaine <Redacted B4>.%microsomal base cream, <Redacted B4> kg, lot 05072021 :72, exp 11/03/21, compounded 05/07/21 to fill Rxl <Redacted B6> (non-patient specific)

• Doxycycline (vet) <Redacted B4> mglmL suspension, <Redacted B4> mL, lot 11292021 :39, exp 05/28/22, compounded 11/29/21 to fill Rx <Redacted B6> l(non-patient specific)

Observation 5

Laboratory controls do not include determination of conformance to appropriate written specifications for the acceptance of each lot within each shipment of components used in the manufacture, processing, packing, or holding of drug products.

Specifically,

Your firm does not perform any analytical testing of incoming raw materials used in the manufacturing of drug products to ensure they conform to requirements for identity, strength, purity, and quality. Your firm has released and distributed numerous lots of drug products without ensuring the components in them are fir for use, including but not limited to the following:

• Lidocaine/Tetracaine <Redacted B4> %LT microsomal base cream, <Redacted B4> kg, lot 05062021 :64, exp 11/02/21, compounded 05/06/21 to fill Rxr <Redacted B6> (non-patient specific)

Observation 6

The batch production and control records are deficient in that they do not include documentation of the accomplishment of each significant step in manufacturing and processing.

Specifically,

a) Your firm does not document actual weights and measurements of components used in the manufacture of drug product on the Logged Formula Worksheets which serve as batch records for drug product lots.

b) Your firm does not document the specific pieces of equipment used in the manufacture of drug product including analytical balances and <Redacted B4> mixing machines.

Due to these practices, your firm has released and distributed numerous lots of drug products for which you do no thave records documenting the actual amounts of the components or specific pieces of equipment that were used to manufacture them, including but not limited to the following:

• Lidocaine/Tetracaine <Redacted B4> % LT microsomal base cream, <Redacted B4> kg, Jot 05062021 :64, exp 11/02/21, compounded 05/06/21 to fill Rx <Redacted B4> (non-patient specific) ...

Read the full 483 (PDF on fda.gov)

State board of pharmacy records

The California State Board of Pharmacy file dated Nov 6, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.

LicenseType as the board gives itName on the board recordCityStatus
PHY 50124Retail PharmacyExpert Compounding Pharmacy IncLake BalboaActive

What this covers: Facility license decisions from the board’s quarterly Disciplinary Actions pages (87 of 88 quarters had a facility section). These are final decisions; accusations filed and immediate protection orders are not included. Actions in the data are dated Jan 5, 2005 to Oct 28, 2026.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.